The DOI matches its Crossref record.
Production of Plasminogen Activator Inhibitor 1 by Human Adipose Tissue: Possible Link Between Visceral Fat Accumulation and Vascular Disease
Abstract
Plasminogen activator inhibitor type 1 (PAI-1) contributes to the pathogenesis of atherothrombosis. Its plasma level is strongly correlated with parameters that define the insulin resistance syndrome, in particular with BMI and visceral accumulation of body fat, suggesting that PAI-1 may be an adipose tissue–derived circulating peptide. The present study was designed to investigate PAI-1 expression by human adipose tissue and its different cellular fractions. Special interest has been paid to the amount of PAI-1 antigen produced by omental versus subcutaneous fat. PAI-1 protein detected by immunolocalization was present at the stromal and adipocyte levels. PAI-1 mRNA was detected in stromal vascular cells freshly isolated and under culture conditions. It was also detected in whole adipose tissue and adipocyte fraction under culture conditions. The mRNA signal from the adipocyte fraction was detected as early as 2 h of incubation. The increase in PAI-1 mRNA was followed by an increase in PAI-1 antigen in the conditioned medium that was suppressed by treatment with cycloheximide. Transforming growth factor-β1 significantly increased PAI-1 antigen production by the adipocyte fraction, whereas tumor necrosis factor-α did not have any effect. Interestingly, after 5 h of incubation, omental tissue explants produced significantly more PAI-1 antigen than did subcutaneous tissue from the same individual, whereas similar production of leptin by the two territories was observed. These results strongly suggest that human adipose tissue, in particular visceral tissue, can be an important contributor to the elevated plasma PAI-1 levels observed in central obesity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Weyer, C., Funahashi, T., Tanaka, S., Hotta, K., Matsuzawa, Y., Pratley, R. E., & Tataranni, P. A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.5.7463 · Cited by 3,541
Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome
Wajchenberg, B. L. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.6.0415 · Cited by 2,961
Subcutaneous and visceral adipose tissue: Structural and functional differences
Ibrahim, M. M. (2010) · Obesity Reviews · doi:10.1111/j.1467-789x.2009.00623.x · Cited by 2,238
Chronic Inflammation in Obesity and the Metabolic Syndrome
Monteiro, R., & Azevedo, I. (2010) · Mediators of Inflammation · doi:10.1155/2010/289645 · Cited by 1,186
“plasminogen activator inhibitor-1 (PAI-1) [66], IL-6, and CRP [67].”
BackgroundInfluentialCarr, D. B., Utzschneider, K. M., Hull, R. L., Kodama, K., Retzlaff, B. M., Brunzell, J. D., Shofer, J. B., Fish, B. E., Knopp, R. H., & Kahn, S. E. (2004) · Diabetes · doi:10.2337/diabetes.53.8.2087 · Cited by 993
Yang, R.-Z., Lee, M.-J., Hu, H., Pray, J., Wu, H.-B., Hansen, B. C., Shuldiner, A. R., Fried, S. K., McLenithan, J. C., & Gong, D.-W. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00572.2004 · Cited by 884
Miyazaki, Y., Mahankali, A., Matsuda, M., Mahankali, S., Hardies, J., Cusi, K., Mandarino, L. J., & DeFronzo, R. A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.6.8567 · Cited by 726
Bays, H., Mandarino, L., & DeFronzo, R. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030723 · Cited by 664
Diabetes mellitus as a prothrombotic condition
Grant, P. J. (2007) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2007.01824.x · Cited by 443
PAI-1 and the Metabolic Syndrome: Links, Causes, and Consequences
Alessi, M.-C., & Juhan-Vague, I. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000242905.41404.68 · Cited by 390
Self-citationSecretory factors from human adipose tissue and their functional role
Hauner, H. (2005) · Proceedings of the Nutrition Society · doi:10.1079/pns2005428 · Cited by 391
Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk
Juhan-Vague, I., Alessi, M.-C., Mavri, A., & Morange, P. E. (2003) · Journal of Thrombosis and Haemostasis · doi:10.1046/j.1538-7836.2003.00279.x · Cited by 371
Self-citationAlessi, M. C., Bastelica, D., Morange, P., Berthet, B., Leduc, I., Verdier, M., Geel, O., & Juhan-Vague, I. (2000) · Diabetes · doi:10.2337/diabetes.49.8.1374 · Cited by 344
Self-citationEndothelial dysfunction in obesity
Engin, A. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-48382-5_15 · Cited by 255
Chandler, W. L., Alessi, M. C., Aillaud, M. F., Henderson, P., Vague, P., & Juhan-Vague, I. (1997) · Circulation · doi:10.1161/01.cir.96.3.761 · Cited by 245
Self-citationDysfunctional fat cells, lipotoxicity and type 2 diabetes
Defronzo, R. A. (2004) · International Journal of Clinical Practice · doi:10.1111/j.1368-504x.2004.00389.x · Cited by 236
Hirose, H., Kawai, T., Yamamoto, Y., Taniyama, M., Tomita, M., Matsubara, K., Okazaki, Y., Ishii, T., Oguma, Y., Takei, I., et al. (2002) · Metabolism · doi:10.1053/meta.2002.30506 · Cited by 235
The autocrine and paracrine roles of adipokines
Karastergiou, K., & Mohamed-Ali, V. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.11.011 · Cited by 233
The Metabolic Syndrome and Inflammation
Sutherland, J. P., McKinley, B., & Eckel, R. H. (2004) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2004.2.82 · Cited by 243
Samad, F., Uysal, K. T., Wiesbrock, S. M., Pandey, M., Hotamisligil, G. S., & Loskutoff, D. J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.12.6902 · Cited by 226
Plasminogen activator inhibitor-1, adipose tissue and insulin resistance
Alessi, M.-C., Poggi, M., & Juhan-Vague, I. (2007) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32814e6d29 · Cited by 212
Self-citationHayashi, T., Boyko, E. J., McNeely, M. J., Leonetti, D. L., Kahn, S. E., & Fujimoto, W. Y. (2008) · Diabetes · doi:10.2337/db07-1378 · Cited by 207
Lijnen, H. R. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvm007 · Cited by 206
Varma, V., Yao-Borengasser, A., Bodles, A. M., Rasouli, N., Phanavanh, B., Nolen, G. T., Kern, E. M., Nagarajan, R., Spencer, H. J., Lee, M.-J., et al. (2008) · Diabetes · doi:10.2337/db07-0840 · Cited by 194
Adipose tissue and metabolic syndrome: too much, too little or neither
Grundy, S. M. (2015) · European Journal of Clinical Investigation · doi:10.1111/eci.12519 · Cited by 187
Cardiovascular risk of adipokines: a review
Dutheil, F., Gordon, B. A., Naughton, G., Crendal, E., Courteix, D., Chaplais, E., Thivel, D., Lac, G., & Benson, A. C. (2018) · Journal of International Medical Research · doi:10.1177/0300060517706578 · Cited by 87
PAI-1 and diabetes: a journey from the bench to the bedside
Schneider, D. J., & Sobel, B. E. (2012) · Diabetes Care · doi:10.2337/dc12-0638 · Cited by 78
Martel-Pelletier, J., Raynauld, J.-P., Dorais, M., Abram, F., & Pelletier, J.-P. (2016) · Rheumatology · doi:10.1093/rheumatology/kev408 · Cited by 68
Stine, J. G., Schreibman, I. R., Faust, A. J., Dahmus, J., Stern, B., Soriano, C., Rivas, G., Hummer, B., Kimball, S. R., Geyer, N. R., et al. (2022) · Hepatology · doi:10.1002/hep.32274 · Cited by 65
Moran, L. J., Hutchison, S. K., Meyer, C., Zoungas, S., & Teede, H. J. (2009) · Clinical Science · doi:10.1042/cs20080218 · Cited by 59
Adipocytokines: a bridge connecting obesity and insulin resistance
Zhuang, X.-F., Zhao, M.-M., Weng, C.-L., & Sun, N.-L. (2009) · Medical Hypotheses · doi:10.1016/j.mehy.2009.05.036 · Cited by 41
Bastard, J.-P., Vidal, H., Jardel, C., Bruckert, E., Robin, D., Vallier, P., Blondy, P., Turpin, G., Forest, C., & Hainque, B. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801087 · Cited by 35
Metadata
- Authors
- Alessi, M. C., Peiretti, F., Morange, P., Henry, M., Nalbone, G., & Juhan-Vague, I.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 1997-05-01
- Volume
- 46
- Issue
- 5
- Pages
- 860-867
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W1979286266
- Cited by
- 615
- References
- 0
- FWCI
- 23.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
